The inclusion and exclusion criteria for the use of Delamanid (Dlm) drug for Multidrug-resistance (DR)/ Rifampicin-resistance (RR) -TB patients are as follows:

The recommended dose of Bedaquiline (Bdq) for the treatment of Multidrug-resistant (DR)/ Rifampicin-resistant (RR) - TB in adults is:

• Weeks 1 – 2: 400 mg (4 tablets of 100 mg) given orally, once daily
• Weeks 3 – 24: 200 mg (2 tablets of 100 mg) three times per week, for a total dose of 600 mg per week

A patient undergoing Multidrug-resistant (MDR)/ Rifampicin-resistant (RR) -TB treatment​ may be eligible for the use of Bedaquiline (Bdq) based on the following inclusion and exclusion criteria:

Inclusion Criteria

There are some anti-TB drugs that are not included in the conventional Groups A, B and C of anti-TB medicines. 

The table below shows these drugs and the rationale for not including them in longer Multidrug-resistant TB (MDR-TB) regimens.

The anti-TB drugs recommended for the treatment of Multi-drug Resistant (MDR)/ Rifampicin-resistant Tuberculosis (RR-TB) patients are grouped based on their efficacy, safety, experience of use of the drug and drug class.

​

Adverse events may occur during anti-TB treatment and need to be managed using certain drugs.

The table below provides information on specific drugs suggested for managing Adverse Drug Reactions (ADRs) during anti-TB treatment. 

Eligibility Criteria for the Use of Delamanid [Dlm] in MDR/RR-TB Treatment​

Bedaquiline Drug Dosages and Duration

Eligibility Criteria for the Use of Bedaquiline [Bdq] in MDR/RR-TB Treatment​